uniQure to Participate in Multiple Upcoming Industry Conferences in November

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in November:

• Huntington Study Group 2019: Navigating Huntington’s Disease, November 7 – 9, Sacramento, California.
  
  ° Eileen Sawyer, VP of Global Medical Affairs, will give an oral presentation on the study design of our Phase I/II clinical trial of AMT-130 for Huntington’s disease on November 7, and will be participating in the “Research Roundup” roundtable on November 8, at 5:30 p.m. PT.
  
  
• Credit Suisse 28^th Annual Healthcare Conference, November 11 – 13, Scottsdale, Arizona.
  
  ° Members of uniQure’s management team will attend and participate in one-on-one investor meetings throughout the day on Tuesday, November 12.

• 10^th Annual World Orphan Drug Congress, November 11 – 14, Barcelona, Spain.
  
  ° Sander van Deventer, EVP Research & Product Development will participate in the panel discussion “Executive Insights: What technologies need to be unlocked? Discussing all the scientific aspects that are impacting the reality of gene therapy” on Wednesday November 13 at 9:55 a.m. CET.
  
  ° In addition, he will participate in the panel discussion “European Investment Landscape for Cell & Gene Therapy” on Thursday November 14, at 2:40 p.m. CET.
   
• Barclays Gene Editing & Gene Therapy Summit, November 13, New York City.
  
  ° Matt Kapusta, chief executive officer will present a corporate update on Wednesday November 13, at 10:15 a.m. ET. Members of uniQure’s management team will participate in one-on-one investor meetings throughout the day on Wednesday, November 13.
   
• World Federation of Hemophilia Global Forum, November 13 – 14, Montreal, Canada
  
  ° Eileen Sawyer will give an oral presentation on “Interim Results from a Phase 2b trial of Etranacogene Dezaparvovec (AMT-061: AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B”, on Thursday November 14, at 9:00 a.m. ET.
   
• Stifel 2019 Healthcare Conference, November 19 – 20, New York City.
  
  ° Matt Kapusta will present a corporate update on Tuesday November 19 at 9:30 a.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.
   
• 29^th Annual Network for European CNS Transplantation and Restoration (NECTAR) Meeting, November 28 – 29, Cardiff, United Kingdom.
  
  ° Pavlina Konstantinova, VP new therapeutic target development at uniQure, will be presenting “Development of a microRNA-based Gene Therapy for Huntington’s Disease “, on Thursday, November 28 at 10:30 a.m. GMT.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com